Physician profile
Danielle Thomas
NPI 1255837894
$1,446.41
in general payments reported to CMS, 2019-2025
24 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $163 · 2022: $397 · 2023: $374 · 2024: $395 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $194.43 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $164.41 | 2024-2025 | Veozah |
| Amgen INC. | $162.34 | 2022-2023 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.88 | 2022 | |
| Axonics, INC. | $125.00 | 2024 | Bulkamid |
| Abbvie INC. | $94.08 | 2023-2025 | Dalvance |
| Amarin Pharma, INC. | $69.20 | 2021 | |
| La Jolla Pharmaceutical Company | $68.05 | 2023 | Xerava |
| Astrazeneca Pharmaceuticals LP | $48.27 | 2021-2025 | Farxiga |
| Pfizer INC. | $48.14 | 2021 | |
| Lilly USA, LLC | $41.82 | 2022-2023 | Mounjaro |
| Paratek Pharmaceuticals, INC. | $41.00 | 2022-2025 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $29.99 | 2024 | |
| Melinta Therapeutics, LLC | $29.98 | 2021 | |
| Inogen, INC. | $26.90 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $22.83 | 2024 | Inpefa |
| Novartis Pharmaceuticals Corporation | $19.74 | 2024 | |
| Sobi, INC | $17.98 | 2022 | |
| Exact Sciences Corporation | $17.10 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $16.64 | 2024 | Verquvo |
| Shield Therapeutics INC | $15.97 | 2022 | |
| Axsome Therapeutics, INC. | $15.52 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $15.34 | 2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.80 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.